Blogs

antibiotics
A brief history Even though Alexander Fleming discovered the first antibiotic penicillin in 1928, it was introduced into the market as a commercial therapeutic for bacterial infection, only in 1940. It was Gerhard Domaghk who developed the first commercial antibacterial Prontosil, a sulfonamide, in 1930s. The introduction of penicillin marked the beginning of the ‘Golden Era’ for antibiotic discovery. For the next 40 years, many antibiotic classes e.g. β-lactams, aminoglycosides, tetracyclines, macrolides, glycopeptides and fluoroquinolones,
Phenotype
  The tediously long and risk-laden process of translating a discovery in biology to a marketable medical breakthrough starts with identifying a repertoire of molecules that will bring about the desired effect. What is it, really? Let´s start with the basics – the definition of phenotype itself. A phenotype is the physical expression of DNA. Phenotypes are caused by the interactions of the many different proteins created by DNA. A “phenotype” is any type of
drug_delivery
Since 2015, the global injectable/parenteral drug delivery market is growing at a compounded rate of 11.8% and is forecasted to reach $640 million by 2021. It has the potential to soon eclipse oral delivery as the primary route of administration of pharmaceuticals, driven by the increased use of biological drugs.1 In 2017, Nine out of the top 10 products were biopharmaceutics while this number was just one, back in 2003.2 The biologics drug development has
VBC
The healthcare industry has been talking about adopting a ‘value-based care’ for some time now.1 Overall, the healthcare systems globally are going through a ‘volume-to-value’ shift with the key aim to improve patient outcomes, cost-effectively. Value-Based Contracting (VBC) and Real-World Evidence (RWE) are the underlying tools to achieve value-based care. Payers and providers increasingly want to understand the value of money they spend on high cost therapies. Value-based contracts link the contracted drug prices and
RNA
In August 2018, patisiran, a first-in-class therapy was approved in the US and EU to treat the polyneuropathy associated with a genetic disease 002D hereditary transthyretin-mediated amyloidosis. The therapy uses small pieces of ribonucleic acid (RNA) to effectively ‘silence’ a faulty gene, without changing the deoxy ribonucleic acid (DNA) of the patient. This is significant! The Dogma of Molecular Biology has been overturned Watson and Crick demonstrated the double-helical structure of DNA in 1953 and
Repurposing
Translating a discovery in biology to a marketable medical breakthrough is a long drawn, tedious, high-investment, and high-risk process. Drug repurposing / repositioning has turned into a popular strategy of late. Not quite the same as traditional drug development techniques, the strategy is productive, affordable and is associated with reduced risk compared to novel molecular entities. What is it, really? According to NCATS of the US NIH, drug repurposing generally refers to studying a drug